Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryUS firms lead as LSEG acquires Octus from Permira for $3.5bnLaw firmsWill Lewallen22 Oct 2026Global elite firms advise on €10.8bn EQT-QIAGEN dealLaw firmsEliza Winter22 Oct 2026Freshfields Asia arbitration and Singapore head leaves for Gibson DunnLaw firmsEliza Winter19 Oct 2026White & Case targets US in latest partner promotions roundLaw firmsWill Lewallen16 Oct 2026Paul Weiss and Clifford Chance in line for nearly £60m in fees for Apollo-easyJet dealLaw firmsKate Peacock15 Oct 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025Former Freshfields senior partner among recipients in New Year Honours ListLaw firmsTom Cox2 Jan 2025